Drug Trial Radar · NCT07553351
GB06 Phase III Trial for Pediatric Growth Hormone Deficiency
Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
192
Planned (sponsor's estimate)
Start
Jun 6, 2026
Primary completion
Jul 25, 2028
Study completion Oct 24, 2028
Sponsor
- Lead sponsor
- Kexing Biopharm Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy and safety of GB06 (a biosimilar of Norditropin®FlexProTM from Novo Nordisk) for the treatment of growth disorders caused by growth hormone deficiency (GHD) in children. It aims to determine whether the annual height velocity (an index of height growth rate) in children diagnosed with GHD after 52 weeks of GB06 intervention is comparable to that of Norditropin®FlexProTM. To achieve this, the participants will administer GB06 or Norditropin®FlexProTM at 0.035mg/kg/day for 52 consecutive weeks.
Conditions
- Growth Hormone Deficiency (GHD)
- Growth Hormone Deficiency in Children
- Growth Hormone Deficiency, Pediatric
Interventions
GB06Drug
GB06 0.035mg/kg/day by subcutaneous injection for 52 weeks
Norditropin®FlexProTMDrug
Norditropin®FlexProTM 0.035mg/kg/day by subcutaneous injection for 52 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annual height velocity (AHV) at week 52.Time frame: From enrollment to the end of treatment at 52 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chengdu Women and Children Central Hospital
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.